Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia

Leukemia volume 17, pages 1058–1067 (2003)Cite this article

Abstract

The Raf/MEK/ERK kinase cascade plays a critical role in transducing growth signals from activated cell surface receptors. Using ΔMEK1:ER, a conditionally active form of MEK1 which responds to either β-estradiol or the estrogen receptor antagonist 4 hydroxy-tamoxifen (4HT), we previously documented the ability of this dual specificity protein kinase to abrogate the cytokine-dependency of human (TF-1) and murine (FDC-P1 and FL5.12) hematopoietic cells lines. Here we demonstrate the ability of ΔMEK1:ER to activate the phosphatidylinositol 3-kinase (PI3K)/Akt/p70 ribosomal S6 kinase (p70S6K) pathway and the importance of this pathway in MEK1-mediated prevention of apoptosis. MEK1-responsive cells can be maintained long term in the presence of β-estradiol, 4HT or IL-3. Removal of hormone led to the rapid cessation of cell proliferation and the induction of apoptosis in a manner similar to cytokine deprivation of the parental cells. Stimulation of ΔMEK1:ER by 4HT resulted in ERK, PI3K, Akt and p70S6K activation. Treatment with PI3K, Akt and p70S6K inhibitors prevented MEK-responsive growth. Furthermore, the apoptotic effects of PI3K/Akt/p70S6K inhibitors could be enhanced by cotreatment with MEK inhibitors. Use of a PI3K inhibitor and a constitutively active form of Akt, [ΔAkt(Myr+)], indicated that activation of PI3K was necessary for MEK1-responsive growth and survival as activation of Akt alone was unable to compensate for the loss of PI3K activity. Cells transduced by MEK or MEK+Akt displayed different sensitivities to signal transduction inhibitors, which targeted these pathways. These results indicate a requirement for the activation of the PI3K pathway during MEK-mediated transformation of certain hematopoietic cells. These experiments provide important clues as to why the identification of mutant signaling pathways may be the Achilles heel of leukemic cell growth. Leukemia treatment targeting multiple signal transduction pathways may be more efficacious than therapy aimed at inhibiting a single pathway.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 6
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Blalock WL, Weinstein-Oppenheimer C, Chang F, Hoyle PE, Wang XY, Algate PA et al. Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: possible sites for intervention with anti-neoplastic drugs. Leukemia 1999; 13: 1109–1166.

    Article  CAS  Google Scholar 

  2. Lee JR JT, McCubrey JA . The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia. Leukemia 2002; 16: 486–507.

    Article  CAS  Google Scholar 

  3. Franklin RA, McCubrey JA . Kinases: positive and negative regulators of apoptosis. Leukemia 2000; 14: 2019–2034.

    Article  CAS  Google Scholar 

  4. Ruvolo PP . Ceramide regulates cellular homeostasis via diverse signaling pathways. Leukemia 2001; 15: 1153–1160.

    Article  CAS  Google Scholar 

  5. Srinivasa SP, Doshi PD . Extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways cooperate in mediating cytokine-induced proliferation of a leukemia cell line. Leukemia 2002; 16: 244–253.

    Article  CAS  Google Scholar 

  6. Abegg AL, Vickery LE, Bremer ME, Donnelly AM, Doshi PD, Evans ML et al. The enhanced in vitro hematopoietic activity of leridistim, a chimeric dual G-CSF and IL-3 receptor antagonist. Leukemia 2002; 16: 316–326.

    Article  CAS  Google Scholar 

  7. Dexter TM, Garland J, Scott D, Scolnick E, Metcalf D . Growth of factor-dependent hematopoietic precursor cell lines. J Exp Med 1982; 152: 1036–1047.

    Article  Google Scholar 

  8. McCubrey JA, Holland G, McKearn J, Risser R . Abrogation of factor-dependence in two IL-3-dependent cell lines can occur by two distinct mechanisms. Oncogene Res 1989; 4: 97–109.

    CAS  Google Scholar 

  9. McCubrey JA, Steelman LS, Hoyle PA, Blalock WL, Weinstein-Oppenheimer CR, Franklin RA et al. Differential abilities of activated Raf oncoproteins to abrogate cytokine-dependency, prevent apoptosis and induce autocrine growth factor synthesis in human hematopoietic cells. Leukemia 1998; 12: 1903–1929.

    Article  CAS  Google Scholar 

  10. McCubrey JA, Smith SR, Algate PA, de Vente JE, White MK, Steelman LS . Retroviral infection can abrogate the factor-dependency of hematopoietic cells by autocrine and non-autocrine mechanisms depending on the presence of a functional viral oncogene. Oncogene 1993; 8: 2905–2915.

    CAS  Google Scholar 

  11. Wang XY, McCubrey JA . Differential effects of retroviral long terminal repeats on interleukin-3 gene expression and autocrine transformation. Leukemia 1997; 11: 1711–1725.

    Article  CAS  Google Scholar 

  12. McCubrey JA, Steelman LS, Mayo MW, Algate PA, Dellow RA, Kaleko M . Growth promoting effects of insulin-like growth factor-1 on hematopoietic cells: overexpression of introduced IGF-1 receptor abrogates IL-3-dependency of murine factor dependent cells by a ligand-dependent mechanism. Blood 1991; 78: 921–929.

    CAS  Google Scholar 

  13. Algate PA, Steelman LS, Mayo MW, Miyajima A, McCubrey JA . Regulation of the interleukin-3 (IL-3) receptor by IL-3 in the fetal liver-derived FL5.12 cell line. Blood 1994; 83: 2450–2468.

    Google Scholar 

  14. Ihle JN, Witthuhn BA, Quell FW, Yamamoto K, Silvennoinen O . Signaling through the hematopoietic cytokine receptors. Annu Rev Immunol 1995; 13:369–399.

    Article  CAS  Google Scholar 

  15. Kinoshita T, Yokota T, Arai K-I, Miyajima A . Suppression of apoptotic death in hematopoietic cells by signaling through the IL-3/GM-CSF receptors. EMBO J 1995; 14: 266–275.

    Article  CAS  Google Scholar 

  16. Steelman LS, Algate PA, Blalock WL, Wang XY, Prevost KD, Hoyle PE et al. Oncogenic effects of overexpression of the interleukin-3 receptor on hematopoietic cells. Leukemia 1996; 10: 528–542.

    CAS  Google Scholar 

  17. Ruvolo PP, Deng X, May WS . Phosphorylation of Bcl2 and regulation of apoptosis. Leukemia 2001; 15: 515–522.

    Article  CAS  Google Scholar 

  18. Pratt JC, Weiss M, Sieff CA, Shoelson SE, Burakoff SJ, Ravichandran KS . Evidence for a physical association between the Shc-PTB domain and the Bc chain of the granulocyte–macrophage colony-stimulating factor receptor. J Biol Chem 1996; 271: 12137–12140.

    Article  CAS  Google Scholar 

  19. Corey S, Eguinoa A, Puyana-Theall K, Bolen JB, Cantley L, Mollinedo F et al. Granulocyte–macrophage colony-stimulating factor stimulates both association and activation of phosphoinositide 3OH-kinase and src-related tyrosine kinase(s) in human myeloid derived cells. EMBO J 1993; 12: 2681–2690.

    Article  CAS  Google Scholar 

  20. Chang F, Lee JT, Navolanic PM, Steelman JG, Blalock WL, Franklin RA et al. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 2003; 17: 590–603.

    Article  CAS  Google Scholar 

  21. Chang F, Steelman LS, Shelton JG, Lee JT, Navolanic PN, Blalock WL et al. Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway. Int J Oncol 2003; 22: 469–481.

    CAS  PubMed  Google Scholar 

  22. Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, Blalock WL et al. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 2003; 17 (in press).

  23. McCubrey JA, May WS, Duronio V, Mufson A . Serine/threonine phosphorylation in cytokine signal transduction. Leukemia 2000; 14: 9–21.

    Article  CAS  Google Scholar 

  24. Boer AK, Drayer AL, Vellenga E . Effects of overexpression of the SH2-containing inositol phosphatase SHIP on proliferation and apoptosis of erythroid AS-E2 cells. Leukemia 2001; 15: 1750–1757.

    Article  CAS  Google Scholar 

  25. White MK, McCubrey JA . Suppression of apoptosis: role in cell growth and neoplasia. Leukemia 2001; 15: 1011–1021.

    Article  CAS  Google Scholar 

  26. Mirza A, Kohn AD, Roth RA, McMahon M . Oncogenic transformation of cells by a conditionally active form of the protein kinase Akt/PKB. Cell Growth Diff 2000; 11: 279–292.

    CAS  PubMed  Google Scholar 

  27. Jucker M, Sudel K, Horn S, Wegner W, Fiedler W, Feldman RA . Expression of a mutated form of the p85alpha regulatory subunit of phosphatidylinositol 3-kinase in a Hodgkin's lymphoma-derived cell line (CO). Leukemia 2002; 16: 894–901.

    Article  CAS  Google Scholar 

  28. Abe M, Suzuki K, Inagaki O, Sassa S, Shikama H . A novel MPL point mutation resulting in thrombopoietin-independent activation. Leukemia 2002; 16: 1500–1506.

    Article  CAS  Google Scholar 

  29. Jordan CT, Upchurch D, Szilvassy SJ, Guzman ML, Howard DS, Pettigrew AL et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 2000; 14: 1777–1784.

    Article  CAS  Google Scholar 

  30. Shelton JG, Steelman LS, Lee JT, Knapp SL, Blalock WL, Moye PM et al. Effects of the Raf/MEK/ERK and PI3K signal transduction pathways on the abrogation of cytokine dependence and prevention of apoptosis in hematopoietic cells. Oncogene 2003 (in press).

  31. Andreeff M, Jiang S, Zhang X, Konopleva M, Estrov Z, Snell VE et al. Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Leukemia 1999; 13: 1881–1892.

    Article  CAS  Google Scholar 

  32. Miranda MB, McGuire TF, Johnson DE . Importance of MEK-1/2 signaling in monocytic and granulocytic differentiation of myeloid cell lines. Leukemia 2002; 16: 683–692.

    Article  CAS  Google Scholar 

  33. Shelly C, Petruzzelli L, Herrera R . PMA-induced phenotypic changes in K562 cells: MAPK-dependent and—independent events. Leukemia 1998; 12: 1951–1961.

    Article  CAS  Google Scholar 

  34. Dent P, Jarvis WD, Birrer MJ, Fisher PB, Sch-Ullrich RK, Grant S . The roles of signaling by the p42/p44 mitogen-activated protein (MAP) kinase pathway; potential route to radio- and chemo-sensitization of tumor cells resulting in the induction of apoptosis and loss of clonogenicity. Leukemia 1998; 12: 1843–1850.

    Article  CAS  Google Scholar 

  35. Ito T, Deng X, Carr B, May WS . Bcl-2 phosphorylation required for anti-apoptosis function. J Biol Chem 1997; 272: 11671–11673.

    CAS  Google Scholar 

  36. Deng X, Ito T, Carr B, May WS . Reversible phosphorylation of Bcl2 following interleukin 3 or bryostatin 1 is mediated by direct interaction with protein phosphatase 2A. J Biol Chem 1998; 273: 34157–34163.

    Article  CAS  Google Scholar 

  37. Scheid MP, Schubert KM, Duronio V . Regulation of Bad phosphorylation and association with Bcl-XL by the MAPK/Erk kinase. J Biol Chem 1999; 274: 31108–31113.

    Article  CAS  Google Scholar 

  38. Blalock WL, Pearce M, Steelman LS, Franklin RA, McCarthy SA, Cherwinski H et al. A conditionally active form of MEK1 abrogates cytokine dependency in human and mouse hematopoietic cells. Oncogene 2000; 19: 526–536.

    Article  CAS  Google Scholar 

  39. Blalock WL, Moye PW, Chang F, Pearce M, Steelman LS, McMahon M et al. Combined effects of aberrant MEK1 activity and BCL2 overexpression on relieving the cytokine-dependency of human and murine hematopoietic cells. Leukemia 2000; 14: 1080–1096.

    Article  CAS  Google Scholar 

  40. Blalock WL, Pearce M, Chang F, Lee J, Pohnert SC, Burrows C et al. Effects of inducible MEK1 Activation on the cytokine-dependency of lymphoid cells. Leukemia 2001; 15: 794–807.

    Article  CAS  Google Scholar 

  41. Davies SP, Reddy H, Caivano M, Cohen P . Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000; 351: 95–105.

    Article  CAS  Google Scholar 

  42. Kohn D, Takeuchi F, Roth RA . Akt, a pleckstrin homology domain containing kinase, is activated primarily by phosphorylation. J Biol Chem 1996; 271: 21920–21926.

    Article  CAS  Google Scholar 

  43. Auger KR, Serunian LA, Soltoff SP, Libby P, Cantley LC . PDGF-dependent tyrosine phosphorylation stimulates production of novel polyphosphoinositides in intact cells. Cell 1989; 57: 167–175.

    Article  CAS  Google Scholar 

  44. Zhang FX, Rubin R, Rooney TA . N-methyl-D-aspartate inhibits apoptosis through activation of phosphatidylinosito 3-kinase in cerebellar granule neurons. A role for insulin receptor substrate-1 in the neurotrophic action of n-D-aspartate and its inhibition by ethanol. J Biol Chem 1998; 273: 26596–25602.

    Article  CAS  Google Scholar 

  45. Hoyle PE, Moye PW, Steelman LS, Blalock WL, Franklin RA, Pearce M et al. Differential abilities of the Raf family of protein kinases to abrogate cytokine-dependency and prevent apoptosis in murine hematopoietic cells by a MEK1-dependent mechanism. Leukemia 2000; 14: 642–656.

    Article  CAS  Google Scholar 

  46. Johnson DE . Noncaspase proteases in apoptosis. Leukemia 2000; 14: 1695–1703.

    Article  CAS  Google Scholar 

  47. Johnson DE . Programmed cell death regulation: basic mechanisms and therapeutic opportunities. Leukemia 2000; 14: 1340–1344.

    Article  CAS  Google Scholar 

  48. Antoku K, Liu Z, Johnson DE . IL-3 withdrawal activates a CrmA-insensitive poly (ADP-ribose) polymerase cleavage enzyme in factor-dependent myeloid progenitor cells. Leukemia 1998; 12: 682–689.

    Article  CAS  Google Scholar 

  49. Antoku K, Liu Z, Johnson DE . Inhibition of caspase proteases by CrmA enhances the resistance of human leukemic cells to multiple chemotherapeutic agents. Leukemia 1997; 10: 1665–1672.

    Article  Google Scholar 

  50. Boudard D, Sordet O, Vasselon C, Revol V, Bertheas MF, Freyssenet D et al. Expression and activity of caspases 1 and 3 in myelodysplastic syndromes. Leukemia 2000; 14: 2045–2051.

    Article  CAS  Google Scholar 

  51. Blagosklonny MV . Cell death beyond apoptosis. Leukemia 2000; 14: 1502–1508.

    Article  CAS  Google Scholar 

  52. Harada H, Andersen JS, Mann M, Terada N, Korsmeyer SJ . p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule Bad. Proc Natl Acad Sci USA 2001; 98: 9666–9670.

    Article  CAS  Google Scholar 

  53. Zwiebel JA . New agents for acute myelogenous leukemia. Leukemia 2000; 14: 488–490.

    Article  CAS  Google Scholar 

  54. Vrana JA, Wang Z, Rao AS, Tang L, Chen JH, Kramer LB et al. Induction of apoptosis and differentiation by fludarabine in human leukemia cells (U937): interactions with the macrocyclic lactone bryostatin 1. Leukemia 1999; 13: 1046–1055.

    Article  CAS  Google Scholar 

  55. O'Gorman DM, McKenna SL, McGahon AJ, Knox KA, Cotter TG . Sensitisation of HL60 human leukaemic cells to cytotoxic drug-induced apoptosis by inhibition of PI3K-kinase survival signals. Leukemia 2000; 14: 602–611.

    Article  CAS  Google Scholar 

  56. Porosnicu M, Nimmananapalli R, Nguyen D, Worthington E, Perkins C, Bhalla KN . Co-treatment with As203 enhances selective cytotoxic effects of STI-571 against Bcr-Abl positive acute leukemia cells. Leukemia 2001; 15: 772–778.

    Article  CAS  Google Scholar 

  57. Damiano JS, Hazlehurst LA, Dalton WS . Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and gamma-irradiation. Leukemia 2001; 15: 1232–1239.

    Article  CAS  Google Scholar 

  58. Zhao M, Kiyoi H, Yamamoto Y, Ito M, Towatari M, Omura S et al. In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor. Leukemia 2000; 14: 374–378.

    Article  CAS  Google Scholar 

  59. Tse KF, Novelli E, Civin CI, Bohmer FD, Small D . Inhibition of FLT-3 mediated transformation by use of a tyrosine kinase inhibitor. Leukemia 2001; 15: 1001–1010.

    Article  CAS  Google Scholar 

  60. Teller S, Kramer D, Bohmer SA, Tse KF, Small D, Mahboobi S et al. Bis(1H-2-indolyl)-1-methanones as inhibitors of the hematopoietic tyrosine kinase Flt3. Leukemia 2002; 16: 1528–1534.

    Article  CAS  Google Scholar 

  61. Minami Y, Kiyoi H, Yamamoto Y, Yamamoto K, Ueda R, Saito H et al. Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors. Leukemia 2002; 16: 1536–1540.

    Article  Google Scholar 

Download references

Acknowledgements

We thank Ms Catherine Spruill for the excellent artwork. This work was supported by grants from the United States National Institutes of Health (R01CA51025) and grants from the North Carolina Biotechnology Center (9805-ARG-0006, 2000-ARG-0003) to JAM. RAF was supported in part by grants from the American Cancer Society (IRG-97-149), American Heart Association (9930099N) and the North Carolina Biotechnology Center (9705-ARG-0009). MKW was supported in part by Public Health Services Grants DK45718 from the National Institutes of Health.

Author information

Author notes

  1. W L Blalock

    Present address: Shands Cancer Center, University of Florida, Gainesville, FL 32610, USA

Authors and Affiliations

  1. Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, NC, USA

    W L Blalock, P M Navolanic, L S Steelman, J G Shelton, P W Moye, J T Lee, R A Franklin & J A McCubrey

  2. Leo Jenkins Cancer Center, Brody School of Medicine at East Carolina University, Greenville, NC, USA

    R A Franklin & J A McCubrey

  3. UCSF/Mt. Zion Cancer Center, San Francisco, CA, USA

    A Mirza & M McMahon

  4. Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson College of Medicine, Philadelphia, PA, USA

    M K White

Authors
  1. W L Blalock
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P M Navolanic
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L S Steelman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J G Shelton
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P W Moye
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J T Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R A Franklin
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A Mirza
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M McMahon
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M K White
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. J A McCubrey
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Blalock, W., Navolanic, P., Steelman, L. et al. Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia. Leukemia 17, 1058–1067 (2003). https://doi.org/10.1038/sj.leu.2402925

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2402925

Keywords

This article is cited by

Search

Advanced search

Quick links